CAS 104056-83-9: b-D-Glucopyranoside,(1R,2R)-2-hydroxy-2-[(1E,3R)-3-hydroxy-1-buten-1-yl]-1,3,3-trimethylcyclohexyl

Rehmaionoside B is a phytochemical compound, which is a natural product derived from the roots of medicinal plants, particularly those in the genus Rehmannia. It is classified as an iridoid glycoside, a group of secondary metabolites known for their diverse biological activities. Rehmaionoside B is sourced through extraction and isolation from plant materials, involving meticulous separation processes to ensure purity and stability. The mode of action of Rehmaionoside B involves modulating biochemical pathways and exerting anti-inflammatory, antioxidant, and potentially neuroprotective effects. Studies suggest that it interacts with cellular signaling pathways, influencing the expression and activity of enzymes and proteins involved in inflammation and oxidative stress responses. The uses and applications of Rehmaionoside B are primarily in the field of pharmaceuticals and nutraceuticals. As an emerging compound of interest, it holds potential for the development of novel therapeutic agents targeting inflammatory diseases, oxidative stress-related conditions, and neurodegenerative disorders. Ongoing research is evaluating its efficacy, safety, and mechanism of action in various experimental models, aiming to elucidate its full therapeutic potential. Despite its promise, clinical applications remain in the exploratory stages, necessitating further studies to validate its utility and benefit in medical practice.